Kornimate/medical-research-clean huggingface dataset:
hyperlipidemia and statin therapy in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the role of hyperlipidemia and lipid lowering therapy (llt) in amyotrophic lateral sclerosis (als) pathophysiology and its impact on disease progression and survival is unclear. the investigators analyzed the correlation between lipid levels with disease progression and survival in als patients and the association of llt with these outcomes.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of laboratory-supported probable, probable, or definite familial, sporadic als, according to a modified el escorial criteria (ref), by the study investigators * time from disease onset is less than three years * 18 years of age * subjects with diagnosis of hyperlipidemia and/or taking lipid lowering medications will not be excluded from study. exclusion criteria: * requirement for tracheotomy ventilation or non-invasive ventilation for \> 23 hours per day * diagnosis of other neurodegenerative diseases (parkinson disease, alzheimer disease, etc) * a clinically significant history of significant medical illness (advanced cancer, chronic inflammatory/infectious conditions, etc) within six months of baseline * use of progestins, anabolic steroids, and corticosteroids within 45 days of baseline visit. therapy is allowed as medically indicated after baseline visit.

Keywords: lipid lowering therapy survival alsfrs age bmi weight
a study of gdc-0853 in patients with resistant b-cell lymphoma or chronic lymphocytic leukemia.

Conditions: Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

Summary: this open-label, phase i study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of gdc-0853 in patients with relapsed or refractory b-cell non-hodgkin's lymphoma or chronic lymphocytic leukemia. in a dose-expansion part, gdc-0853 will be assessed in subsets of patients.


Eligibility criteria:
inclusion criteria: * age \>/= 18 years * ecog score of 0-1 * one of the following histologically-documented hematologic malignancies for which no effective standard therapy exists: indolent non hodgkin's lymphoma (nhl), follicular lymphoma (fl), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), or chronic lymphocytic leukemia (cll) * at least one site of disease that, as seen on ct scan, is \> 1.5 cm in the greatest transverse diameter or \> 1.0 cm in short axis diameter (except for patients with cll) * an available tumor specimen * adequate hematologic and organ function * for female patients of childbearing potential and male patients with partners of childbearing potential, use of effective contraceptive(s) as defined by protocol for the duration of the study exclusion criteria: * life expectancy \< 12 weeks * \< 3 weeks since the last anti-tumor therapy, including chemotherapy, biologic, experimental, hormonal or radiotherapy (with the exception of leuprolide or similar medications for prostate cancer) * recent major surgical procedure or traumatic injury, or unhealed incisions or wounds * active infection requiring iv antibiotics * clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis. * primary cns malignancy or untreated/active cns metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) * history of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, stage i uterine cancer, or other cancers with a similar outcome * cardiovascular dysfunction, including ventricular dysrhythmias or risk factors for ventricular dysrhythmias * pregnancy, or lactation * any other diseases that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
blend to limit oxygen in ecmo: a randomised controlled registry trial

Conditions: Cardiac Failure; Critical Illness

Summary: to determine in patients requiring venoarterial (v-a) ecmo, whether the use of a conservative as compared with liberal oxygen strategy, results in a greater number of icu-free days at day 28.

extracorporeal membrane oxygenation (ecmo) can be a lifesaving procedure for the sickest patients in the intensive care unit (icu) who are at risk of death from severe cardiac and respiratory failure. ecmo is a device which pumps blood out of the body and returns it back after adding oxygen and removing carbon dioxide. while potentially life-saving, ecmo is associated with high use of critical care resources and increased risk of adverse outcomes in survivors. the blender trial is a multicentre trial in ecmo patients to determine whether a conservative oxygen strategy during ecmo reduces icu length of stay and improves patient outcomes compared to a liberal oxygen strategy. both strategies are currently standard practice worldwide, however, there is no consensus to which strategy is better for our patients. this trial aims to utilise an existing intensive care registry and will recruit 300 patients with life threatening acute cardiac or respiratory failure. if the blender trial confirms that one oxygen management strategy is more effective than the other, its findings may improve the lives of critically ill australians and inform clinical practice worldwide.

Eligibility criteria:
inclusion criteria: • patients ≥18 years who are commenced on v-a ecmo for severe cardiac, or following refractory cardiac arrest. exclusion criteria: * greater than 6 hours have elapsed from the time of initiation of ecmo to randomisation * patients who are suspected or confirmed to be pregnant * where an indication exists for a specific oxygen target as part of clinical care (e.g. carbon monoxide poisoning) * patients who are already enrolled in another oxygen titration study (unless agreed by study committees) * patients not willing to receive blood products (e.g. jehovah's witness) * where the treating physician deems the study is not in the patient's best interest

Keywords: ecmo v-a ecmo oxygen hyperoxia
phenotypes of preschool wheezing among children attending sohag university hospital

Conditions: Wheezing

Summary: wheezing in preschool children is very common, with a wide differential diagnosis. it is essential to be sure of the exact sound that parents are describing; the term 'wheeze' is often applied to non-specific sound.approximately one-third of children are diagnosed with wheeze in the first 3 years of life, making wheeze one of the commonest respiratory symptoms.the differential diagnosis of wheeze is wide, and different management strategies are needed depending on the underlying phenotype. the word 'wheeze' is used to describe many different sounds. that can be heard by both clincians and parent. even if true wheeze is heard, this should not be automatically assumed to be due to bronchospasm. airway narrowing by mucus will produce true wheeze but does not respond to bronchodilators. similarly, airway malacia, either related to intrinsic airway wall defects or loss of alveolar tethering points, are also causes of bronchodilatorunresponsive wheeze; indeed, bronchodilators, by reducing airway smooth muscle tone, may actually worsen airway narrowing.


Eligibility criteria:
inclusion criteria: * patients from the age of one to five years with recurrent wheezing exclusion criteria: * children above 5 years and below one year old. * failure to obtain informed consent. * children below 6 years with chest diseases other than wheezing
efficacy of rpms for improvement of urinary incontinence and female sexual function

Conditions: Urinary Incontinence

Summary: evaluation of the repetitive pulse magnetic stimulation (rpms) for the treatment of urinary incontinence and a female sexual satisfaction.


Eligibility criteria:
inclusion criteria: * age between 21 and 65 years * voluntarily signed informed consent form * suffers from ui * sexually active * fsfi questionnaire score ≤ 26.55 points exclusion criteria: * suffers from other types of urinary incontinence other than sui, uui, mui * currently lactating * cardiac pacemakers * implanted defibrillators and/or neurostimulators * electronic implants * metal implants, including copper iud * drug pumps * hemorrhagic conditions * anticoagulation therapy * fever * pregnancy * following recent surgical procedures when muscle contraction may disrupt the healing process * application over areas of the skin which lack normal sensation
analysis of tpe treatments with multifiltratepro

Conditions: Autoimmune Diseases

Summary: analysis of therapeutic plasma exchange (tpe) treatments to assess the performance of the tpe mode of multifiltratepro based on the successful exchange of plasma from whole blood. the multifiltratepro is a device for extracorporeal blood purification treatments.

the study is a retrospective, open, non-comparative, multi-centric pmcf study. the investigational device has ce approval. the investigation involves the retrospective collection of treatment data for the tpe treatment mode from the medical records. no further control treatments will be investigated in this one-arm design. the design is considered to be appropriate to reflect daily clinical practice and to contribute to empirical evidence of performance of the tpe mode of the multifiltratepro system. the site will document the treatment data of patients with an indication for the tpe treatment who had been treated with the investigational devices under the tpe treatment mode between 2019 and october 2023 in chronological order.

Eligibility criteria:
inclusion criteria: * body weight ≥40kg irrespective of the age * patients with indication for tpe treatment according to asfa guideline * patients have been treated with tpe between january 2019 and october 2023 * availability of at least 50% of the parameters to be documented for the patient exclusion criteria: * participation in an interventional clinical study during the retrospectively collected tpe treatment data * previous documentation within this study * simultaneous use of another filter for additional therapy form

Keywords: therapeutical plasma exchange asfa guideline
anti-recurrence treatment of postresection on hcc patients with mvi presence and over-expression of asph

Conditions: Hepatocellular Carcinoma

Summary: the aim of this study is to explore the effect of transarterial chemoembolization (tace) on the prognosis of patients with microvascular invasion presence(mvi) and overexpression of aspartate-β-hydroxylase(asph).


Eligibility criteria:
inclusion criteria: 1. via clinical diagnosis and confirm it is primary liver cancer 2. pathological evidence of hcc 3. confirm presence of mvi and over-expression of asph after opreation 4. within milan criteria 5. estimate tumor can gain treatment of curing operation 6. no evidence for extrahepatic metestasis 7. liver function ：child-pugh a/b exclusion criteria: 1. reject to attend 2. impossible to come to our hospital for physical examination regularly 3. patients with apparent cardiac, pulmonary, cerebral and renal dysfunction 4. female with pregnancy or during the lactation period

Keywords: recurrence microvascular invasion aspartate beta-hydroxylase
fitness and sleep in people with family history of type 2 diabetes.

Conditions: Sleep; Physical Fitness; Type 2 Diabetes

Summary: currently, it is not known if the amount of nighttime sleep has any effect on the overall physical fitness, and on how much energy do people who have a relative with type 2 diabetes (parent, sibling, or grandparent) use to perform activities of daily living. this study will test the hypothesis that individual differences in nighttime sleep duration are related to differences in the amount of energy used to perform activities of daily living and the overall level of physical fitness of the individual.

the study includes 2 weeks of monitoring of the participants' patterns of sleep and wakefulness at home. at the beginning of this period, all participants will undergo measurements of their body composition (lean tissue, bone and fat) and their metabolic rate at rest and after a standard meal. at that time, all participants will also drink a glass of water containing harmless non-radioactive dense forms of oxygen and hydrogen, small amounts of which are found in natural water. several urine samples will be collected before and after the participants drink the water at the beginning of the study and again 14 days later in order to measure the amount of energy that was used by them during this time. participants will also wear small wristwatch-like activity monitors on their wrist and around their waist as they follow their usual everyday activities and sleep-wake schedules at home. the recordings from these monitors combined with daily sleep logs will be used to determine when the participants slept and when they were awake. on the last day of the study, the participants will undergo mri measurements of the distribution of fat in their abdomen and complete a graded exercise test on a treadmill or stationary bicycle in order to determine what is the most strenuous level of exercise that they can perform. a medical doctor will supervise all study procedures that are done in the research laboratory.

Eligibility criteria:
inclusion criteria: * regular sleep habits * bmi 20 to 27 kg/m2 * at least one parent, sibling or grandparent with type 2 diabetes * no regular exercise habits exclusion criteria: * active smoker * night or shift work * have highly variable sleep habits * have a hormonal disorder * have a sleep disorder * have an active medical problem * for women: use of birth control pills * for women: irregular menstrual periods or pregnancy * use of medications/compounds that can disrupt sleep

Keywords: short sleep duration maximal aerobic capacity body fat visceral adiposity activity-related energy expenditure energy metabolism
explainable insulin decision-making system to assist physicians in diabetes management

Conditions: Diabetes

Summary: the investigators plan to conduct a multi-case, multi-reader observational study with the primary objective of exploring the effects of an interpretable insulin-assisted decision-making system on physicians' (1) decision accuracy and (2) decision confidence.


Eligibility criteria:
case: inclusion criteria: * patients with t2dm who were admitted to zhongshan hospital of fudan university from 2022.12 to 2023.3. * insulin regimen is one of the following: a. basal regimen: once a day subcutaneous injection of long-acting or ultra-long-acting insulin; b. premixed regimen: two/three times a day subcutaneous injection of premixed insulin; c. basal mealtime regimen: three times a day before meals subcutaneous injection of short-acting or rapid-acting insulin, plus once a day injection of long-acting or ultra-long-acting insulin. exclusion criteria: - cases will be excluded if there is insufficient information for a valid assessment (missing data on insulin or blood glucose \>40%). doctor inclusion criteria: licensed medical practitioner.
alternative in beta blocker intolerance: the abbi trial

Conditions: Coronary Artery Disease

Summary: in this study the investigators will assess the tolerance of nebivolol (bystolic) in cardiovascular patients who are not able to tolerate conventional beta blockers. a side effect profile will be tracked and compared with previous beta blocker use. the investigators hypothesize that bystolic will be tolerated by many patients who are intolerant of conventional blockers.

patients who have been prescribed standard beta blockers but were unable to tolerate them due to side effects will be studied. they will take a new beta blocker, nebivolol (bystolic) for 30 days, if tolerated. side effects will be tracked and compared to previous.

Eligibility criteria:
inclusion criteria: * age ≥ 21 * male or female who is post-menopausal or not pregnant and using an approved contraceptive regimen * previous beta blocker use and intolerant of beta blocker exclusion criteria: * systolic blood pressure \< 100 mmhg unless another blood pressure medication is stopped at the time of study entry * hospitalized for heart failure within the past 4 weeks * bradycardia with a heart rate \< 60 * heart block greater than first degree * history of sick sinus syndrome (unless a permanent pacemaker is in place) * history of severe hepatic or renal dysfunction; serum creatinine \> 2.0 or amylase \> 3x normal * use of cyp2d6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) * ingestion of investigational drug within the past 30 days

Keywords: intolerance beta blocker
neurotrophins implications in primary sjögren syndrome

Conditions: Primary Sjögren Syndrome

Summary: neurotrophins (nts) constitute a family of growth factors, which regulated differentiation, proliferation, and survival of both neuronal cells and astrocytes. in recent years, several studies have provided evidences that the cellular effects of ngf " nerve growth factor ", bdnf " brain-derived neurotrophic factor " and nt-3 are not limited to the nervous system. indeed, neurotrophins and their receptors are widely expressed on non neuronal cells. data concerning the implication of nts and their receptors in the immune system maturation and in the regulation of normal and pathological immune responses are numerous and suggest the existence of a specific "neuro-immunomodulation" through these neuropeptides. the aim of the study is to compare sjögren's syndrome systemic activity to seric, lymphocytic and conjunctival levels of nts (i.e ngf, bdnf and nt-3). a preliminary study has previously pointed out the link between high bdnf seric levels and sjögren's systemic activity. the increased levels of bdnf were correlated to t cell activation. a similar correlation between high ngf level and hypergammaglobulinemia was also pointed out.

2 supplementary blood sample for determination of seric and lymphocytic nt profile will be added to a standard biological analysis done for pss follow- up. salivary sicca syndrome will be evaluated with un-stimulated salivary flow rate. saliva fluid will be collected from nts levels determination (elisa). ocular sicca syndrome will be evaluated by schirmer tests and lissaline green test. a conjunctival cytological impression will be done in order to determine nts conjunctival production by flow cytometry.

Eligibility criteria:
inclusion criteria: arm : primary sjögren syndrome: * all patients must fulfill the revised criteria for primary sjögren syndrome. * age of entry into the study ≥ 18 yrs. * affiliated or profit patient of a social security system. * informed consent signed up. arm : healthy volunteers: * all patient free of autoimmune disease. * age of entry into the study ≥ 18 yrs. * affiliated or profit patient of a social security system. * informed consent signed up. exclusion criteria: * patient with psychiatric disorders not related with antiphospholipid syndrome and / or cerebral complication of sgsp. * addictive behaviors (alcoholism, cocaine or opioid abuse). * patient with anti-depressive drugs. * patient with concurrent malignancy * pregnancy * patients under measure of maintenance of justice. * patients unable to understand or to participate to the study. * child and major patients making the object of a measure of lawful protection. * patients deprived of freedom. exclusion criteria for control group * autoimmune disease. * steroid treatment (\>20 mg/day). * immunosuppressive treatment. * concurrent malignancy. * concurrent psychiatric disorders. * anti-depressive drugs. * pregnancy.

Keywords: primary sjögren syndrome neurotrophins b cell sicca syndrome t cell
effects of activity versus structural oriented treatment approach in patients with frozen shoulder.

Conditions: Frozen Shoulder

Summary: the aim of this study is to compare the effects of activity versus structural oriented treatment approach on pain, range of motion, and function in diabetic patients with frozen shoulder.

frozen shoulder, also known as adhesive capsulitis, is a condition of uncertain etiology, characterized by shoulder stiffness, severe pain, significant restriction of range of motions, and limitation in participation in socio-economical life. according to a concept, pain causes changes in the brain making it learn the non-use, and therefore, even after healing of peripheral structures has occurred, the brain may not be able to organize voluntary actions owing to the induced central changes. physical therapy plays an important role to bring pain relief and return of functional motion in frozen shoulder and there are many approaches available that can be used but literature on treatments based on neuroplasticity is comparatively less. according to the research available, neuroplasticity has been effective in treating frozen shoulder. similarly, pnf, home exercises, and joint mobilizations have also proven to be effective. the effects of the activity related and structural-oriented treatment on the frozen shoulder has not been addressed in diabetic patients yet. more rcts are required to determine the best treatment for managing adhesive capsulitis in diabetics. therefore, this research will be conducted which will compare the activity-based approach and the conventional approach to treating frozen shoulder in diabetics. the results may open new aspects of treating frozen shoulder in diabetics which can be cost-effective as well.

Eligibility criteria:
inclusion criteria: * diagnosed with frozen shoulder, limited rom, and pain in the shoulder region * patients with diabetes from 10+ years exclusion criteria: * history of headaches and dizziness * pain and limited rom in the cervical spine * pain and limited rom in temporomandibular joint

Keywords: frozen shoulder manual therapy proprioceptive neuromuscular facilitation neuroplasticity diabetes